Downregulated FET with GnRH Agonist 0.1 mg Protocol
The downregulated frozen embryo transfer (FET) protocol using GnRH agonist 0.1 mg involves starting triptorelin in the mid-luteal phase of the preceding cycle, reducing the dose when estrogen begins, and stopping it when progesterone supplementation starts, with embryo transfer timed to endometrial thickness and embryo developmental stage.
Protocol Steps
Phase 1: Pituitary Downregulation
- Start GnRH agonist (triptorelin) 0.1 mg subcutaneously daily beginning in the mid-luteal phase of the cycle immediately before your planned FET cycle 1
- Continue this dose until menstruation begins
Phase 2: Endometrial Preparation
- On cycle day 2: Reduce triptorelin to 0.05 mg daily subcutaneously 1
- Simultaneously start: Estradiol valerate 6 mg orally daily 1
- Continue both medications for approximately 12 days while monitoring endometrial development
Phase 3: Luteal Support
- After 12 days of estrogen: Add micronized progesterone 400 mg vaginally twice daily 1
- Stop the GnRH agonist when progesterone begins 1
- Continue estrogen and progesterone through embryo transfer
Phase 4: Embryo Transfer
- Transfer timing: When endometrial thickness reaches ≥12 mm 1
- Embryo selection: Transfer embryos on day +1 of their chronological age 1
- Number of embryos: Transfer single embryo (eSET) to minimize multiple pregnancy complications 2
Evidence Supporting This Protocol
The downregulation approach shows significant benefits in specific populations:
- Improved implantation rates: 44.1% vs 21.1% compared to HRT alone (P=0.002) 1
- Higher pregnancy rates: 65.5% vs 42% compared to HRT alone (P=0.013) 1
- Particular benefit in advanced maternal age (≥35 years): Live birth rates improve significantly in women ≥35 years with GnRH agonist downregulation 3, 4
Clinical Rationale
The GnRH agonist downregulation likely works by:
- Creating a more controlled hormonal environment by suppressing endogenous LH surges
- Optimizing endometrial receptivity through complete pituitary suppression before estrogen priming
- Enhancing implantation-related factors in the endometrium 4
Important Caveats
Age considerations: While the protocol shows clear benefits in women ≥35 years 3, 4, evidence is mixed for younger women. Some studies show no significant benefit in women <35 years 5, 3, though the original protocol study included all ages 1.
Conflicting evidence exists: Not all studies support GnRH agonist use in FET. Single-dose administration at transfer (rather than downregulation protocol) shows no benefit 6, 5, emphasizing that the timing and duration of GnRH agonist administration matters—the downregulation protocol starting in the preceding cycle differs fundamentally from single-dose approaches.
Embryo Transfer Number
Transfer only one embryo (eSET), particularly if transferring blastocysts, regardless of patient age or prior failed cycles 2. Double embryo transfer dramatically increases risks of:
- Multiple pregnancy complications
- Pre-eclampsia and gestational diabetes
- Preterm birth and low birthweight
- Ectopic pregnancy (up to 20-fold increase) 2
- Neonatal morbidity and mortality
The 2024 ESHRE guidelines strongly emphasize that no evidence supports double embryo transfer improving cumulative live birth rates, even in poor prognosis patients, while risks are substantially elevated 2.